NYSE:CRY - New York Stock Exchange, Inc. - Common Stock
17.88
+0.25 (+1.42%)
The current stock price of CRY is 17.88 null. In the past month the price decreased by -10.29%. In the past year, price decreased by -29.19%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.89 | 222.95B | ||
ISRG | INTUITIVE SURGICAL INC | 73.73 | 201.89B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.14 | 152.31B | ||
SYK | STRYKER CORP | 30.91 | 147.82B | ||
MDT | MEDTRONIC PLC | 15.82 | 108.34B | ||
BDX | BECTON DICKINSON AND CO | 12.22 | 49.43B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.65 | 45.32B | ||
IDXX | IDEXX LABORATORIES INC | 44.68 | 41.28B | ||
RMD | RESMED INC | 27.26 | 36.30B | ||
DXCM | DEXCOM INC | 51.93 | 33.60B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.87 | 33.43B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.72 | 22.46B |
CryoLife, Inc. engages in the manufacture, process and distribution of medical devices. The company is headquartered in Kennesaw, Georgia and currently employs 1,200 full-time employees. The firm is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The firm operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.
CRYOLIFE INC
1655 Roberts Blvd NW
Kennesaw GEORGIA 30144 US
CEO: J. Patrick Mackin
Employees: 1200
Phone: 17704193355.0
The current stock price of CRY is 17.88 null. The price increased by 1.42% in the last trading session.
The exchange symbol of CRYOLIFE INC is CRY and it is listed on the New York Stock Exchange, Inc. exchange.
CRY stock is listed on the New York Stock Exchange, Inc. exchange.
8 analysts have analysed CRY and the average price target is 33.09 null. This implies a price increase of 85.05% is expected in the next year compared to the current price of 17.88. Check the CRYOLIFE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CRYOLIFE INC (CRY) has a market capitalization of 703.22M null. This makes CRY a Small Cap stock.
CRYOLIFE INC (CRY) currently has 1200 employees.
CRYOLIFE INC (CRY) has a support level at 17.84 and a resistance level at 17.99. Check the full technical report for a detailed analysis of CRY support and resistance levels.
The Revenue of CRYOLIFE INC (CRY) is expected to grow by 18.02% in the next year. Check the estimates tab for more information on the CRY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRY does not pay a dividend.
CRYOLIFE INC (CRY) will report earnings on 2022-02-10.
The PE ratio for CRYOLIFE INC (CRY) is 59.6. This is based on the reported non-GAAP earnings per share of 0.3 and the current share price of 17.88 null. Check the full fundamental report for a full analysis of the valuation metrics for CRY.
ChartMill assigns a fundamental rating of 4 / 10 to CRY. While CRY is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months CRY reported a non-GAAP Earnings per Share(EPS) of 0.3. The EPS increased by 130.77% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -0.37% | ||
ROA | -0.16% | ||
ROE | N/A | ||
Debt/Equity | 1 |
ChartMill assigns a Buy % Consensus number of 83% to CRY. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -91.22% and a revenue growth 18.02% for CRY